Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · TELA Bio, Inc. (TELA)

TELA Bio gets lender waiver of minimum revenue covenant for two 2026 quarters

Neutral Impact 3 of 5 financing Written later

TELA Bio entered into a Limited Consent to its credit agreement on September 28, 2026, with Perceptive Credit Holdings V, LP, as administrative agent, and the Required Lenders. The consent means the minimum Revenue covenant in Section 10.02 of the credit agreement will not be tested for the quarters ending on or about September 30, 2026 and December 31, 2026. The filing does not state the reason for the consent.

Key points

  • Limited Consent dated September 28, 2026, amending the credit agreement dated November 13, 2025
  • Minimum Revenue covenant in Section 10.02 not tested for quarters ending on or about September 30, 2026 and December 31, 2026
  • Administrative agent: Perceptive Credit Holdings V, LP
  • Full text to be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2026

The filing

CompanyTELA Bio, Inc. (TELA)
Form8-K, current report
Filed with the SECSep 29, 2026, 4:05 PM ET
Accession number0001104659-26-111920

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.